EMMA (Emmaus Life Sciences) Accounts Payable: $5.81 Mil (As of Mar. 2026)


What is Emmaus Life Sciences Accounts Payable?

Emmaus Life Sciences EMMA +14.37% Accounts Payable is $5.81 Mil as of Mar. 2026. The stock has 6 warning signs investors should review.

Emmaus Life Sciences's Accounts Payable for the quarter that ended in Mar. 2026 was $5.81 Mil.

Emmaus Life Sciences's quarterly Accounts Payable declined from Sep. 2025 ($5.36 Mil) to Dec. 2025 ($4.03 Mil) but then increased from Dec. 2025 ($4.03 Mil) to Mar. 2026 ($5.81 Mil).

Emmaus Life Sciences's annual Accounts Payable declined from Dec. 2023 ($3.63 Mil) to Dec. 2024 ($3.31 Mil) but then increased from Dec. 2024 ($3.31 Mil) to Dec. 2025 ($4.03 Mil).

Emmaus Life Sciences Accounts Payable Related Terms

Emmaus Life Sciences Accounts Payable Historical Data

* Premium members only.

The historical data trend for Emmaus Life Sciences's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emmaus Life Sciences Accounts Payable Chart

Emmaus Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.72 3.79 3.63 3.31 4.03

Emmaus Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.25 4.56 5.36 4.03 5.81

Emmaus Life Sciences Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $5.81 Mil mean?
Emmaus Life Sciences (EMMA) has a Accounts Payable of $5.81 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Emmaus Life Sciences and its competitors.
Is Emmaus Life Sciences' Accounts Payable too high?
Emmaus Life Sciences' current Accounts Payable is $5.81 Mil.
How does Emmaus Life Sciences' Accounts Payable compare to PTIX and BZYR?
Emmaus Life Sciences' Accounts Payable of $5.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Emmaus Life Sciences and its competitors. Emmaus Life Sciences's current Accounts Payable is $5.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 17% above its estimated fair value. The current Accounts Payable is $5.81 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Accounts Payable is $5.81 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emmaus Life Sciences Business Description

Address 21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.